The high-stakes legal battle between Apple and Oppo reaches a critical deadline as the Chinese smartphone maker must provide forensic evidence about a former Apple engineer accused of stealing proprietary technology. This case highlights growing tensions in the global wearables market.
The Enterprise Demand for Brand-Specific AI When Adobe launched Firefly, its generative AI engine, the company expected enthusiasm from creative…
In a surprising regulatory development, Novo Nordisk allegedly failed to maintain patent protection for its blockbuster drug semaglutide in Canada. The oversight could enable generic competition years earlier than expected in one of the world’s largest markets for the GLP-1 medication.
In what industry analysts are calling a remarkable regulatory oversight, pharmaceutical company Novo Nordisk reportedly allowed its patent for the popular diabetes and weight loss drug semaglutide to lapse in Canada by failing to pay maintenance fees, according to recent reports. The situation came to light during an interview with Sandoz CEO Richard Saynor, who revealed his company plans to launch a generic version of the GLP-1 drug in Canada as early as 2026.
How EA’s $55 Billion Privatization Will Transform Gaming Experiences Electronic Arts stands as one of gaming’s most iconic publishers, responsible…
TITLE: OpenAI Granted Relief from ChatGPT Data Preservation Order, With Key Exceptions Federal Court Modifies OpenAI’s Data Retention Requirements A…
